De-Risking Complexity In Pharmaceutical Manufacturing

By Klaus Stingl, Global Head BD & Sales Drug Substance

Rising molecular complexity, compressed development timelines, and increasing pressure to control costs are reshaping pharmaceutical development. As APIs become more challenging to synthesize and regulatory pathways continue to accelerate, developers must find new ways to reduce risk while maintaining speed and quality.

Success increasingly depends on combining deep process development expertise with flexible manufacturing strategies that can adapt across the product lifecycle. Scalable synthetic routes, resilient supply chains, and phase-appropriate development approaches help organizations navigate technical challenges, manage capacity demands, and prepare for commercialization with greater confidence.

Equally important is access to integrated capabilities that support a seamless transition from development through commercial production. When process optimization, supply planning, and manufacturing expertise are aligned early, teams can respond more effectively to uncertainty and keep critical milestones on track.

Explore strategies for navigating complexity while accelerating the path to patients.